Premium
The chronic myeloid leukaemia story in the United Kingdom since 1960
Author(s) -
Clark Richard E.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17149
Subject(s) - chronic myeloid leukaemia , life expectancy , medicine , myeloid leukaemia , disease , chronic disease , pediatrics , intensive care medicine , immunology , environmental health , population
Summary Over the past 60 years, haematologists and scientists from the United Kingdom, notably John Goldman and Tessa Holyoake, have punched above their weight in changing chronic myeloid leukaemia (CML) from an incurable and invariably fatal disease for all, to a chronic condition where over 90% have normal life expectancy. As a result, it is now difficult to power a worthwhile phase 3 study for newly diagnosed patients. Nevertheless, important clinical questions remain.